Table 1.
Baseline characteristics*
| DMARD (n = 117) | All anti-TNF (n = 177) | P | |
|---|---|---|---|
| Age, mean ± SD years | 66 ± 10 | 62 ± 10 | 0.002 |
| Women, % | 74 | 81 | 0.110 |
| DAS28, mean ± SD | 5.0 ± 1.3 | 6.7 ± 1.2 | 0.0001 |
| HAQ score, mean ± SD | 1.6 ± 0.7 | 2.2 ± 0.5 | 0.0001 |
| Disease duration, median (IQR) years | 9 (2–18) | 11 (6–18) | 0.0083 |
| Prior DMARDs, median (IQR) | 2 (1–4) | 4 (3–5) | 0.0001 |
| Baseline steroid use | 39 (33) | 90 (51) | 0.003 |
| Smoking | |||
| Current | 25 (21) | 32 (18) | 0.011 |
| Former | 61 (52) | 67 (38) | |
| Never | 31 (27) | 77 (44) | |
| Entry year | |||
| Pre-2003 | 0 | 15 (8) | < 0.0001 |
| 2003 | 6 (5) | 57 (32) | |
| 2004 | 27 (23) | 49 (28) | |
| 2005 | 41 (35) | 28 (16) | |
| 2006 or after | 43 (37) | 28 (16) | |
| Prior malignancy | |||
| Solid | 96 (82) | 147 (83) | 0.795 |
| Lymphoproliferative | 11 (9) | 13 (7) | |
| Melanoma | 10 (8) | 17 (10) | |
| Time from most recent prior malignancy to registration | |||
| Median (IQR) years | 8.5 (4.7–14.1) | 11.5 (5.8–17.1) | 0.027 |
| >10 years preregistration | 46 (39) | 102 (58) | 0.002 |
*
Values are the number (percentage) unless otherwise indicated. DMARD = disease-modifying antirheumatic drug; anti-TNF = anti–tumor necrosis factor; DAS28 = Disease Activity Score in 28 joints; HAQ = Health Assessment Questionnaire; IQR = interquartile range.